PHARMA M&A WAVE SET TO REACH INDIA

While merger-mania is gripping the global pharma industry, a similar trend may soon spill over to the Indian market, with pharma companies quoting at low valuations and saddled with huge debt.

Recently, there have been a spate of deals in the pharma space led by Pfizer Inc's acquisition of Wyeth for $68 billion, followed by the merger of Merck and Schering Plough. Experts believe that Bristol-Myers Squibb may be the next target of an acquisition, and many more deals are inevitable. Back home, there has been speculation about Wockhardt and Piramal Healthcare being potential acquisition targets.

The Times Of India

INDIAN FIRMS EMPLOY OVER 30K US CITIZENS

Amidst the row in US over outsourcing, a study has said that big corporates like Essar, HCL, Tata, Mahindra and Wipro have generated over 30,000 jobs for Americans in recent years.

The Financial Express

Daiichi-Ranbaxy may signal Big Pharma-generic deals

Daiichi Sankyo Co Ltd's for control of Ranbaxy Laboratories Ltd that pharmaceutical companies have a major appetite for generic drugmakers despite concerns about differences in their business models.

Reuters
http://in.reuters.com/article/asiaCompanyAndMarkets/
idINN1144380420080611?sp=true